Title: An Age-group Analysis on the Efficacy of Chemotherapy in Older Adult Patients with
Metastatic Biliary Tract Cancer: A Japanese Cancer Registry Cohort Study
Version: 2 Date: 04 May 2023
Reviewer's report:
Thank you for your submitting the manuscript.  Tolerability significantly matters when systemic
chemotherapy undergoes for older patients, especially more than 70 years old. Your manuscript
is of importance to know and encourages physicians undergoing systemic chemotherapies for
older patients, but lack the data of what factors are leading to successful systemic chemotherapies
even in older patients over 70 years old. Randomized Phase III study of gemcitabine plus S-1
versus gemcitabine plus cisplatin in advanced biliary tract cancer, FUGA trial included older
patients less than age of 80. I believe this evidence is a kind of guideline for treating unresectable
bile duct cancer in Japan. I also reviewed that the recently published research focusing on
older patients from FUGA trial. It was well written in informative details ( Sci Rep. 2022 Jan
19;12(1):987.doi: 10.1038/s41598-021-04550-8) .
Title: An Age-group Analysis on the Efficacy of Chemotherapy in Older Adult Patients with
Metastatic Biliary Tract Cancer: A Japanese Cancer Registry Cohort Study
Version: 2 Date: 04 May 2023
Reviewer's report:
Thank you for your submitting the manuscript.  Tolerability significantly matters when systemic
chemotherapy undergoes for older patients, especially more than 70 years old. Your manuscript
is of importance to know and encourages physicians undergoing systemic chemotherapies for
older patients, but lack the data of what factors are leading to successful systemic chemotherapies
even in older patients over 70 years old. Randomized Phase III study of gemcitabine plus S-1
versus gemcitabine plus cisplatin in advanced biliary tract cancer, FUGA trial included older
patients less than age of 80. I believe this evidence is a kind of guideline for treating unresectable
bile duct cancer in Japan. I also reviewed that the recently published research focusing on
older patients from FUGA trial. It was well written in informative details ( Sci Rep. 2022 Jan
19;12(1):987.doi: 10.1038/s41598-021-04550-8) .
Please review this paper.
user
Title: An Age-group Analysis on the Efficacy of Chemotherapy in Older Adult Patients with
Metastatic Biliary Tract Cancer: A Japanese Cancer Registry Cohort Study
Version: 2 Date: 04 May 2023
Reviewer's report:
Thank you for your submitting the manuscript.  Tolerability significantly matters when systemic
chemotherapy undergoes for older patients, especially more than 70 years old. Your manuscript
is of importance to know and encourages physicians undergoing systemic chemotherapies for
older patients, but lack the data of what factors are leading to successful systemic chemotherapies
even in older patients over 70 years old. Randomized Phase III study of gemcitabine plus S-1
versus gemcitabine plus cisplatin in advanced biliary tract cancer, FUGA trial included older
patients less than age of 80. I believe this evidence is a kind of guideline for treating unresectable
bile duct cancer in Japan. I also reviewed that the recently published research focusing on
older patients from FUGA trial. It was well written in informative details ( Sci Rep. 2022 Jan
19;12(1):987.doi: 10.1038/s41598-021-04550-8) .
assistant